Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Bristol Myers Squibb's experimental drug admilparant showed success at a lower dose in a late-stage trial for idiopathic pulmonary fibrosis (IPF), a progressive and irreversible lung-scarring disease. The 60 mg twice-daily dose significantly outperformed placebo in preserving lung function at 52 weeks, while the higher 120 mg dose fell short. If approved, admilparant would be the first-ever LPA1 inhibitor to treat IPF.
Bristol Myers Squibb's experimental drug admilparant cleared a major hurdle in its late-stage trial for idiopathic pulmonary fibrosis (IPF), a serious and progressive lung-scarring disease with limited treatment options. The 60 mg twice-daily dose significantly outperformed placebo in preserving lung function over 52 weeks — though the higher 120 mg dose missed the trial's primary endpoint. Both doses were well-tolerated, with discontinuation rates comparable to placebo.
Admilparant works by blocking the LPA1 protein receptor, a pathway involved in lung scarring, making it a first-of-its-kind mechanism if it earns regulatory approval. Current IPF therapies include Boehringer Ingelheim's Ofev and Jascayd, and Roche's Esbriet — but none target the LPA1 pathway. Results from a separate late-stage trial in progressive pulmonary fibrosis are expected in early 2027.
By the Numbers:
Why it matters: IPF is a devastating disease with no cure, and new treatment options are urgently needed. A first-in-class LPA1 inhibitor could meaningfully expand the therapeutic landscape for patients who have few alternatives.
